Informing Endpoints for Clinical Trials of Geographic Atrophy.

Annu Rev Vis Sci

Department of Ophthalmology, Center for Public Health, Queen's University, Belfast, Northern Ireland, United Kingdom; email:

Published: September 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Geographic atrophy (GA), the non-neovascular advanced form of age-related macular degeneration, remains an important disease area in which treatment needs are currently unmet. Recent clinical trials using drugs that target the complement pathway have shown modest yet consistent reductions in GA expansion but without commensurate changes in measures of visual function. In this review, we summarize information from the wide range of studies describing the characteristics of GA morphology and enumerate the factors influencing the growth rates of lesions and the directionality of expansion. In addition, we review the relationship between GA growth and the various measures of vision that reflect changes in function. We consider the reasons for the discordance between the anatomical and functional endpoints in current use and discuss methods to align these key outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-vision-101922-045110DOI Listing

Publication Analysis

Top Keywords

clinical trials
8
geographic atrophy
8
informing endpoints
4
endpoints clinical
4
trials geographic
4
atrophy geographic
4
atrophy non-neovascular
4
non-neovascular advanced
4
advanced form
4
form age-related
4

Similar Publications

Season of Blood Pressure Measurement Screening and All-Cause Mortality: A Community-Based Prospective Cohort Study.

Hypertension

September 2025

Department of Hypertension, Center for Epidemiological Studies and Clinical Trials, the Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (J.W.).

Background: The association between season of screening blood pressure (BP) measurement and adverse outcomes has not been examined among populations without prior physician-diagnosed hypertension. We aimed to investigate the association between the season of screening clinic BP measurement and the risk of all-cause mortality.

Methods: This was a prospective cohort study, and data were analyzed from an ongoing community hypertension screening program in Shanghai between 2018 and 2024.

View Article and Find Full Text PDF

Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.

View Article and Find Full Text PDF

Background: According to the Council of International Organizations and Medical Sciences (CIOMS) 2016, post-trial access (PTA) refers to the ethical imperative that requires the sponsor, researchers, and relevant public health authority, "to make available as soon as possible any intervention or product developed, and knowledge generated, for the population or community in which the research is carried out." Law, policy, and practical guidance for PTA has so far been vague but has recently attracted and increased attention in the context of benefit sharing of scientific research results with low- and middle-income countries (LMICs).Although the number of clinical trials conducted in the Sub Saharan (SSA) countries has increased in the past two decades, plans and practices for PTA are underreported.

View Article and Find Full Text PDF

This systematic review and meta-analysis aimed to evaluate the long-term clinical outcomes of regenerative procedures compared with access flap surgery for the treatment of intrabony defects, with a minimum follow-up period of 5 years. A systematic review protocol following PRISMA guidelines was conducted. Both electronic and manual searches were conducted to identify randomized clinical trials (RCTs) on regenerative treatment of deep intrabony defects (≥3 mm) with a follow-up of at least 5 years.

View Article and Find Full Text PDF

Radical esophagectomy remains the cornerstone of curative treatment for esophageal cancer, but is frequently complicated by postoperative events, most notably anastomotic leakage. Anastomotic leakage, occurring in up to 30% of cases, is multifactorial in origin and significantly increases morbidity and mortality. This review aims to summarize current management strategies, highlight emerging therapies, and identify persistent clinical challenges related to this complication.

View Article and Find Full Text PDF